Mechanisms of tau and Aß-induced excitotoxicity.

Excitotoxicity was originally postulated to be a late stage side effect of Alzheimer׳s disease (AD)-related neurodegeneration, however more recent studies indicate that it may occur early in AD and contribute to the neurodegenerative process. Tau and amyloid beta (Aß), the main components of neurofibrillary tangles (NFTs) and amyloid plaques, have been implicated in cooperatively and independently facilitating excitotoxicity. Our study investigated the roles of tau and Aß in AD-related excitotoxicity. In vivo studies showed that tau knockout (tau(-/-)) mice were significantly protected from seizures and hippocampal superoxide production induced with the glutamate analog, kainic acid (KA). We hypothesized that tau accomplished this by facilitating KA-induced Ca(2+) influx into neurons, however lentiviral tau knockdown failed to ameliorate KA-induced Ca(2+) influx into primary rat cortical neurons. We further investigated if tau cooperated with Aß to facilitate KA-induced Ca(2+) influx. While Aß biphasically modulated the KA-induced Cacyt(2+) responses, tau knockdown continued to have no effect. Therefore, tau facilitates KA-induced seizures and superoxide production in a manner that does not involve facilitation of Ca(2+) influx through KA receptors (KAR). On the other hand, acute pretreatment with Aß (10 min) enhanced KA-induced Ca(2+) influx, while chronic Aß (24 h) significantly reduced it, regardless of tau knockdown. Given previously published connections between Aß, group 1 metabotropic glutamate receptors (mGluRs), and KAR regulation, we hypothesized that Aß modulates KAR via a G-protein coupled receptor pathway mediated by group 1 mGluRs. We found that Aß did not activate group 1 mGluRs and inhibition of these receptors did not reverse Aß modulation of KA-induced Ca(2+) influx. Therefore, Aß biphasically regulates KAR via a mechanism that does not involve group 1mGluR activation.

An integrated cellular and sub-cellular model of cancer chemotherapy and therapies that target cell survival.

Apoptosis resistance is a hallmark of human cancer, and tumor cells often become resistant due to defects in the programmed cell death machinery. Targeting key apoptosis regulators to overcome apoptotic resistance and promote rapid death of tumor cells is an exciting new strategy for cancer treatment, either alone or in combination with traditionally used anti-cancer drugs that target cell division. Here we present a multiscale modeling framework for investigating the synergism between traditional chemotherapy and targeted therapies aimed at critical regulators of apoptosis.

Light scattering measurement and Avrami analysis of the lamellar to inverse hexagonal phase transition kinetics of the lipid DEPE.

The lamellar to inverse hexagonal phase transition of lipids is much studied as a model for understanding cellular processes such as membrane fusion and pore formation. Much remains unknown, including a theoretical understanding and a definitive value of the phase transition temperature for DEPE, as literature values vary over 10°C. Avrami theory has been commonly used to analyze phase transition kinetics. However, to the best of our knowledge, Avrami theory has not been used to analyze the lamellar to inverse hexagonal transition in lipids until now. We used laser light scattering to measure phase transition temperature of the lipid DEPE (1,2-dielaidoyl-sn-phosphatidylethanolamine) and found it to be 61.0 ± 0.5°C. We found the hysteresis, |T(measured)-T(equilibrium)|, scaled as r(ß), where r is the ramp rate and ß=0.29 ± 0.02. This is the same power law behavior found by others for an isomer of DEPE known as DOPE (1,2-dioleoyl-sn-glycero-3 ethanolamine); however, DEPE exhibits roughly half the hysteresis of DOPE. An analysis of DEPE kinetics yields Avrami exponents ranging from 1 to 7, suggesting the transition propagates one dimensionally and is initiated by a widely varying nucleation rate.

The SLAM family member CD48 (Slamf2) protects lupus-prone mice from autoimmune nephritis.

Polymorphisms in the SLAM family of leukocyte cell surface regulatory molecules have been associated with lupus-like phenotypes in both humans and mice. The murine Slamf gene cluster lies within the lupus-associated Sle1b region of mouse chromosome 1. Non-autoreactive C57BL/6 (B6) mice that have had this region replaced by syntenic segments from other mouse strains (i.e. 129, NZB and NZW) are B6 congenic strains that spontaneously produce non-nephritogenic lupus-like autoantibodies. We have recently reported that genetic ablation of the SLAM family member CD48 (Slamf2) drives full-blown autoimmune disease with severe proliferative glomerulonephritis (CD48GN) in B6 mice carrying 129 sequences of the Sle1b region (B6.129CD48(-/-)). We also discovered that BALB/c mice with the same 129-derived CD48-null allele (BALB.129CD48(-/-)) have neither nephritis nor anti-DNA autoantibodies, indicating that strain specific background genes modulate the effects of CD48 deficiency. Here we further examine this novel model of lupus nephritis in which CD48 deficiency transforms benign autoreactivity into fatal nephritis. CD48GN is characterized by glomerular hypertrophy with mesangial expansion, proliferation and leukocytic infiltration. Immune complexes deposit in mesangium and in sub-endothelial, sub-epithelial and intramembranous sites along the glomerular basement membrane. Afflicted mice have low-grade proteinuria, intermittent hematuria and their progressive renal injury manifests with elevated urine NGAL levels and with uremia. In contrast to the lupus-like B6.129CD48(-/-) animals, neither BALB.129CD48(-/-) mice nor B6 × BALB/c F1.129CD48(-/-) progeny have autoimmune traits, indicating that B6-specific background genes modulate the effect of CD48 on lupus nephritis in a recessive manner.